Compass Therapeutics, Inc. (CMPX) Up 200% Year-on-Year

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock surged 237.08% in the past year and 16.05% year-to-date. On April 7, John Newman of Cannaccord Genuity maintained a Buy rating on Compass Therapeutics with a price target of $13.00.

Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?

In March, Compass Chief Executive Officer and Vice Chairman of the Board of Directors Thomas Schuetz, MD, PhD, expressed excitement over the upcoming results of the phase 2 study for its tovecimig. He said:

“2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study in patients with biliary tract cancer. We are excited to report the results of the key secondary endpoints next month. The upcoming tovecimig PFS (progression-free survival)/ overall survival (OS) data release could be transformational for the company, and we are looking forward to the new option it would bring for patients with biliary tract cancer.”

He shared that the company’s novel PD-1 x PD-L1 checkpoint inhibitor, CTX-8371, also demonstrated strong clinical activity this past year, with three robust responses in patients with both solid tumors and hematologic malignancies, all observed in heavily pre-treated patients who received prior checkpoint inhibitor therapies.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.

While we acknowledge the risk and potential of CMPX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 5 Stocks with Double Digit Returns.

Disclosure: None. Follow Insider Monkey on Google News.